# A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects

> **NCT02436928** · PHASE1,PHASE2 · COMPLETED · sponsor: **Medigen Vaccine Biologics Corp.** · enrollment: 200 (actual)

## Conditions studied

- H7N9 Influenza Vaccine

## Interventions

- **BIOLOGICAL:** AT-501 High Dose vaccine
- **BIOLOGICAL:** AT-501 High Dose vaccine with Adjuvant
- **BIOLOGICAL:** AT-501 Low Dose vaccine
- **BIOLOGICAL:** AT-501 Low Dose vaccine with Adjuvant

## Key facts

- **NCT ID:** NCT02436928
- **Lead sponsor:** Medigen Vaccine Biologics Corp.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2016-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02436928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02436928, "A Study to Evaluate the Safety and Immunogenicity of H7N9 Influenza Vaccine (AT-501) in Healthy Adult Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02436928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*